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inTRoDucTion
Lung cancer remains the deadliest cancer worldwide 
whereby the non-small cell lung cancer (NSCLC) subtype 
accounts for ~85% of all lung cancers. Standard of care is 
a multimodal approach including surgery, radiotherapy, 
chemotherapy and targeted therapy, often administered 
in combination. Despite improvements in treatment tech-
niques, overall survival has only marginally improved for 
advanced (Stage III–IV) lung cancer, and treatment cost 
has escalated.1
There is mounting evidence that the current pre–clinical 
mouse models for cancer treatment testing predict clinical 
response poorly. The most widely used models for anti-
cancer drug testing are subcutaneous tumor xenografts. 
However, these models fail to recapitulate the interactions of 
the tumor with its microenvironment, which may influence 
response to chemotherapy2 and radiotherapy.3 Treatment 
resistance is partly due to a deficient tumor vasculature 
impeding normal blood flow and thus, both drug and 
nutrient delivery to the tumor.4 Hence, a greater emphasis 
on reproducible and physiologically relevant preclinical 
tumor models is required to assess efficacy and toxicity of 
new interventions that target tumor progression and recur-
rence. Orthotopic tumor models are able to overcome, at 
least partially, this limitation. Orthotopically implanted 
NSCLC or spontaneous KRAS-induced lung tumors are 
thought to have better vasculature functionality.5
In addition, to improving cancer models that reflect 
advanced disease, quantitative non-invasive imaging 
modalities to monitor tumor progression and treatment 
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objective: Lung cancer is the deadliest cancer worldwide. 
To increase treatment potential for lung cancer, pre-clin-
ical models that allow testing and follow up of clinically 
relevant treatment modalities are essential. Therefore, we 
developed a single-nodule-based orthotopic non-small 
cell lung cancer tumor model which can be monitored 
using multimodal non-invasive imaging to select the 
optimal image–guided radiation treatment plan.
methods: An orthotopic non-small cell lung cancer 
model in NMRI-nude mice was established to investi-
gate the complementary information acquired from 80 
kVp microcone-beam CT (micro–CBCT) and biolumi-
nescence imaging (BLI) using different angles and filter 
settings. Different micro–CBCT-based radiation-delivery 
plans were evaluated based on their dose–volume histo-
gram metrics of tumor and organs at risk to select the 
optimal treatment plan.
Results: H1299 cell suspensions injected directly into the 
lung render exponentially growing single tumor nodules 
whose CBCT–based volume quantification strongly 
correlated with BLI–integrated intensity. Parallel–
opposed single angle beam plans through a single lung 
are preferred for smaller tumors, whereas for larger 
tumors, plans that spread the radiation dose across 
healthy tissues are favored.
conclusions: Closely mimicking a clinical setting for 
lung cancer with highly advanced preclinical radia-
tion treatment planning is possible in mice developing 
orthotopic lung tumors.
advances in knowledge: BLI and CBCT imaging of 
orthotopic lung tumors provide complementary infor-
mation in a temporal manner. The optimal radiotherapy 
plan is tumor volume-dependent.
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response dynamically in time such as the ones used in this 
study: CT and bioluminescence imaging (BLI), must be opti-
mized. CT is suitable for longitudinal monitoring and accurate 
delineation of tumors for radiotherapy treatment planning.6 
Repeated—daily or multiple times per week for several weeks 
– use of CT should however be avoided because of the cumu-
lative radiation dose to healthy tissues.7 Studies using phan-
toms, and confirmed in small rodents, indicate that in order to 
increase precision, there must be an increase in the isotropic 
voxel size (thus decreasing image resolution) or an increase in 
the X-ray dose.7 Recent improvements in detector technology 
have enabled enhanced resolution, however, high-quality 
images approach a lethal X-ray dose.7 Therefore, image quality 
must be compromised to deliver doses as low as reasonably 
achievable to avoid bias in therapeutic efficacy and warrant 
animal welfare.8 Additionally, tumor growth can be affected by 
doses greater than 1 Gy,8 and depending on the sensitivity of 
the tumor, repeated CT scans could improve cancer morbidity 
by delaying tumor progression in certain tumor types.9 BLI on 
the other hand, is a highly sensitive, non-invasive and radia-
tion-free imaging modality that requires the expression of a 
luciferase enzyme to catalyze D-luciferin into oxyluciferin and 
light.10,11 There is a gradual increase in tissue penetration at 
longer wavelengths and higher photon energies, potentially 
enabling insight on tumor depth.12 However, light scattering, 
tissue penetration and absorption, makes absolute BLI quanti-
fication challenging.
Precision image-guided small animal radiotherapy (SmART) 
research platforms with an integrated cone beam CT (CBCT) 
scanner and BLI have become available which allows 1 mm 
precision sized beams for radiation delivery to minimize normal 
tissue toxicity.13,14 We recently demonstrated that there was good 
correlation between micro-CT calculated tumor volume and BLI 
signal in a temporal manner for histopathologically confirmed 
intracranial brain tumors.15 Radiation planning, using SmART-
Plan software,16 enables dose-volume calculations prior to 
delivery for design optimization and has been implemented for 
CT image-guided radiation planning of brain tumors to inves-
tigate combinations of conventional treatment regimens17 and 
novel targeted drugs.18 In this study we assessed this correlation 
for intrapulmonary NSCLC and investigated tumor volume-de-
pendent differences in optimal radiation planning.
meTHoDS anD maTeRialS
Orthotopic tumor cell injection
NCI–H1299 and A549 NSCLC cells were cultured in 
DMEM medium whereas NCI-H460 was cultured in RPMI 
1640 (Westburg) medium, supplemented with 10% fetal 
calf serum (Sigma–Aldrich). The origin of the cell lines is 
available at ATCC. To establish luciferase-expressing cells, 
H1299-GFP-luciferase19 and A549–luc–C820 cells were gener-
ated as previously described. Cell line identity was confirmed 
by short-tandem repeat analysis (Identicell, Denmark) and 
tested for the presence of mycoplasma prior to their injection 
in 2536g NMRI-nude male mice (Charles River). Orthot-
opic implantation of tumor cells was performed as previously 
described but with modifications.21 A small incision, parallel 
to the ribs, after the third “false rib” and the first “floating rib”, 
was made and the muscles were carefully lifted using blunt 
scissors and considering muscle orientation to allow lung 
visualization through the rib cage and avoid lung collapse and 
pneumothorax. Specifically, 106 tumor cells resuspended in 
10–20 µL mixture (4:1) of Matrigel (Corning)—CT contrast 
agent (Omnipaque 350, GE Healthcare), were injected into 
the middle/upper lobe of the right lung, were movement is the 
least, using a 25G needle at a depth 6 mm (reference depth 
point: rib cage) between the seventh and eighth ribs (starting 
count in the first posterior “false rib”) at maximal inhala-
tion. Wound closure was obtained with 3M™ vetbond tissue 
adhesive (Bio-connect) and surgical suture. Pre-operative 
(Buprenorphine 0.1 mg kg–1) and post-operative (Carprofen 
5 mg kg–1) analgesia were applied. At the end of the exper-
iment, lungs were excised, formalin (4%)-fixed, paraffin-em-
bedded, sectioned (5 µm), and stained with Hematoxylin and 
Eosin. Images were acquired with a phase contrast microscope 
at 10× magnification and stitched together for full visualiza-
tion. Animal experiments were in accordance with local insti-
tutional guidelines for animal welfare and approved by the 
Animal Ethical Committee of the University of Maastricht.
Micro-cone beam CT (CBCT) imaging and analysis
Multiple two-dimensional thoracic cone beam CT images (80 
kVp, 3 mA, 120 s, 39cGy/scan) were acquired using an X-RAD 
225Cx22 small animal irradiator (Precision X-ray, Inc, North 
Branford, CT)13,14,23 under isoflurane anesthesia. Image projec-
tions were reconstructed using the Feldkamp24 filtered back 
projection (Pilot version 1.1.18; Precision X-ray, Inc), resulting 
in a three-dimensional isotropic pixel spacing of 102 µm. Pre-de-
fined CT window settings of 1550 to −1480 Houndsfield Units 
(HU) for tumor and normal lung (total lung minus tumor), 
and of 250 to −150 HU for heart and spinal cord were used 
for structure delineations using in SmART-Plan.16 Contours 
were exported as bitmasks after applying erosion with a spher-
ical structuring element (1-pixel radius) to decrease inaccura-
cies of the contouring procedure. A three-dimensional bitmask 
was calculated from the two-dimensional contours using the 
poly2mask function in MATLAB R2016b (Mathworks, Natick, 
MA https://www. mathworks. com/ help/ images/ ref/ poly2mask. 
html). The voxels in the bitmask have the same size as the CT 
voxels therefore, the number of voxels in the tumor bitmask 
multiplied by the voxel size will result in the tumor volume. No 
spherical approximation formulas were used. Tumor volume 
(Volumetumor) was calculated according to the formula: Volu-
metumor = (numberVoxels * voxelSpacingX * voxelSpacingY * 
voxelSpacingZ).
Bioluminescence imaging
Under isoflurane anesthesia, whole-body white light and BLI 
scans from six angles (0, 90, 180, 225, 270, and 315 degrees 
corresponding to left, ventral, right, diagonal right, dorsal, 
and diagonal left sides respectively) were acquired with the 
iXon Ultra 897 camera (Andor Technology Ltd, Belfast, UK) 
in the X–RAD 225Cx using no (open modus), 591.5 or 655 
nm filters 26 min after intraperitoneal injection of D-lucif-
erin (300 µl solution, 15 mg ml−1, in physiological saline). 
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Bioluminescence images were acquired with a gain of 300, an 
opacity at 70% and the signal intensity parameters were kept 
constant for all images (W = 37977.48 and L = 26438.27 for 
white light image, W = 7767.0 and l = 5277.0 for BLI). The 
cumulative raw BLI intensity signal was corrected with the 
background signal corresponding to the average signal in the 
four corners of the image (30×30 pixels).
Radiation treatment planning and dose calculation
Treatment plans based on parallel-opposed static, or two arc 
beams (with angles of 260–272o and 350–360o) using a 3 mm or a 
5 mm circular collimator (SmART-Plan v1.5,16) for two different 
volumes were compared for mean (Dmean), minimum (Dmin) and 
maximum (Dmax) doses, dose to 95% (D95), to 5% (D5), and to 
1% (D1) of the delineated structure volume and the percentage 
of structure volume receiving 95% (V95) of the prescribed 
dose. The beam angle with the best avoidance of organs at risk 
(OARs) was chosen. A 2-min-thoracic CBCT scan acquisition 
time enables imaging throughout the full respiratory cycle of the 
mouse (every 4 s under deep anesthesia), therefore the delin-
eated tumor volume will be referred to as the internal target 
volume (ITV). Errors in planning, temporal tumor movement 
over the course of days, and treatment delivery uncertainties16 
were compensated with an additional 0.5 mm margin (planned 
target volume, PTV). Dose calculations were performed with the 
dose engine DOSXYZnrc (National Research Council Canada, 
Ottawa, ON) using an intrinsic dose uncertainty set to 1% in the 
target volume. The conversion of CT number to material type 
and density was performed based on a 3-material (air, soft tissue 
and bone) human tissue (International Commission on Radia-
tion units and Measurements, report 44) segmentation scheme. 
A CT number-to-density calibration curve was established 
using a 3 cm diameter preclinical µCT calibration phantom with 
different tissue substitute inserts (SmART Scientific Solutions 
B.V., Maastricht, Netherlands). Dose calculations were run with 
108 particles for each treatment plan.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 
Software (v. 5.03). Normality distribution of tumor volume 
and bioluminescence data were assessed with a D’Agostino and 
Pearson omnibus test. Non-parametric Spearman correlation 
test was applied to determine the relationship between tumor 
volume by CBCT imaging and bioluminescence signal and 
further confirmed by linear regression analysis. A p-value < 0.05 
was considered statistically significant.
ReSulTS
Single orthotopic NSCLC nodules are feasible
Centrally localized tumors in the right lung were obtained after 
H1299 cell suspension injection (Figure  1A). Tumor location 
in the lung was macroscopically and histologically confirmed 
(Figure 1B) and tumor growth was exponential with an average 
doubling time of approximately 9 days (Figure 1C). H1299-lu-
ciferase expressing tumors (including a tumor with a centrally 
located calcification, D8) grew slower with a doubling time of 
approximately 19 days (Figure  1D), and occupying less than 
7% of the right lung volume (or 5% of total lung volume, data 
not shown) after 80 days post-tumor cell implantation in the 
lung (Figure 1E). H460 and A549 cell suspension mixtures led 
to multiple lung nodules in the lung and thoracic cavity and 
experiments with these models were discontinued (data not 
shown). BLI signal intensity in H1299-luciferase expressing 
tumors increased with time and was most intense at the site of 
the tumor (Figure 2A, Supplementary Figure 1A–D in Supple-
mentary Material 1). The BLI signal acquired from the 655 nm 
wavelength was 3-fold greater than that from the 591.5 nm 
wavelength and 12-fold less than the open modus (all wave-
lengths) (Fig 2A, Supplementary Figure 1A-D in Supplementary 
Material 1).
Figure 1. Establishment of single nodule orthotopic NSCLC 
models. (A) Representative 2D delineated CT images of 
selected time points after H1299 cell suspension injection in 
the right lung. Tumors, right and left lung are delineated in red, 
green and blue, respectively. (B) Macroscopic and histologi-
cal confirmation of presence of a single tumor nodule in the 
right lung indicated with an arrow. (C) Tumor quantification 
over time of a representative orthotopic H1299-wildtype lung 
tumor. (D) Tumor quantification over time of three orthotopic 
H1299-luciferase lung tumors: A7, C7, and D8 (presenting a 
central calcification). (E) Normalized H1299-luciferase (from 
D) tumor volumes to total right lung volume quantification. 
NSCLC, non-small cell lung cancer.
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CBCT volume and BLI signal intensity are 
correlated
Bioluminescent signals acquired with open modus correlated 
significantly (r = 0.88 to 0.96, p < 0.0001) with tumor volume 
assessed by CBCT imaging (Figure  2B). Good correlations 
between CT and BLI were also observed for 655 nm (r = 0.84–
0.95, p-value < 0.001), and 591.5 nm (r = 0.75–0.88, p-value < 
0.05) filters (Supplementary Figure 1E in Supplementary Mate-
rial 1). Similar results were obtained with R2 linear regression fits 
(data not shown).
Radiation treatment planning may be volume-
dependent
Tumors and OAR (left lung, right lung, heart and spinal cord) 
were delineated on thoracic CT images of H1299-wt or H1299-lu-
ciferase tumor-bearing mice using SmART-plan software. Visual 
tumor coverage using different radiation beam plans (planned 
dose 2 Gy) with their corresponding dose–volume histograms 
(DVH) are shown for a 4 and 10.4 mm3 H1299 tumor using a 
3 (Figure  3A–B) or 5 mm (Figure  3C–D) collimator, respec-
tively, and quantified in Tables 1 and 2, respectively (Supplemen-
tary tables 1 and 2, (Supplementary Material 1) for a planned 
dose of 20 Gy). The 3 and 5 mm collimator were optimal for a 4 
(Table 1) and 10.4 mm3 (Table 2) tumor respectively, irrespective 
of the tested plan, having a Dmean within the PTV similar to the 
planned dose. The PTV V95 was above 98.7%, independent of the 
tested volume, using the 5 mm collimator, whereas for the 3 mm 
collimator it ranged from 82.3 to 92.8% for a 4 mm3 tumor. As 
expected, the V95 for the 3 mm collimator for a 10.4 mm3 tumor 
was inferior (58.2–76.9%). For a 3 mm collimator, a better PTV 
coverage can be obtained with parallel-opposed-based treatment 
plans from a single angle (Plan 1 and 2) compared to Plan 3 and 
4, while for a 5 mm collimator each plan results in similar PTV 
coverage (Tables 1 and 2). Similar results were obtained for plans 
1 and 2 using calcification-free H1299-luciferase expressing 
tumors A7 and C7 (Supplementary Table 3 in Supplementary 
Material 1). As expected, radiation plans on a calcified tumor 
(D8), were not as precise.
The optimal PTV coverage, however is associated with an 
increased volume of normal lung tissue receiving 95% of the 
delivered dose. Right lung V95 was higher (up to 23.4% for the 
3 mm and up to 35% for 5 mm collimator) in plans 1 and 2 
compared to plans 3 and 4 (up to 4.5% for the 3 mm and up 
to 11% for 5 mm collimator). Remarkably, using a beam setup 
crossing both lungs (Plan 2), similar and only slightly reduced 
V95 values were obtained for the left (Plan 2) and right (Plan 1) 
lung respectively. Despite covering both lungs, employing four 
equally weighted beams instead of two (as in plans 1 and 2) or the 
usage of two arc beams (Plan 4), greatly reduces the dose to the 
normal lung. Normal tissue mean radiation doses for heart and 
spinal cord were minor for any tested plan although the long-
term dose-effects should be experimentally tested (Tables 1 and 
2). Dose uniformity was found to be consistent across treatment 
plans (data not shown).
DiScuSSion
In this study, we established an orthotopic NSCLC model and 
evaluated different radiation treatment plans using non-inva-
sive image guidance. Not all NSCLC cell line models tested here 
resulted in a single localized tumor nodule in the lung. Others 
have reported that blind-percutaneous injection of H1299 cells 
into the left lateral thorax at 5–7 mm of depth, produced solitary 
Figure 2. Correlation between tumor volume determined by 
CBCT and BLI signal intensity over time. (A) Representa-
tive CBCT and 180-angle BLI images (overlaid on the white 
light image of the mouse) over time. (B) Correlation between 
CBCT-derived tumor volume (mm3) and BLI intensity obtained 
from the 180-degree angle for three independent H1299-lucif-
erase expressing tumors. CBCT, cone beam CT; BLI, biolumi-
nescence imaging.
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lesions that progressed into diffuse thoracic disease.25 Mordant et al 
investigated the establishment of orthotopic lung tumors using the 
A549 cells and found that transpleural injections resulted in a 65% 
localized tumor take, followed by 7% locoregional invasion and 3% 
of bone metastasis.26 Also, pleural injection of H460 cells has been 
shown to result in tumors in the lung and the chest wall with 100% 
Figure 3. Volume-dependent radiation treatment planning. Representative beam setup in axial plane for four radiation plans: 
parallel-opposed, equally weighted single angle, static crossing a single lung (Plan 1), crossing both lungs (Plan 2), 2-angle paral-
lel-opposed static (Plan 3), or two equally weighted arc (Plan 4) beams for a H1299 tumor model. Two tumors volumes are shown: 
volume 1 (4 mm3) with the 3 mm collimator (A) and volume 2 (10.4 mm3) with the 5 mm collimator (C), with their corresponding 
dose–volume histograms (B, D respectively). PTV, ITV, right lung, left lung, spinal cord and heart are indicated in green, light blue, 
yellow, pink, dark blue and red, respectively. ITV, internal target volume; PTV, planning targetvolume.
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Table 1. Dose-volume histogram metrics for different structures (ITV, PTV, right/left lung, heart, spinal cord) for a representative 
mouse case bearing a H1299-wt tumor (4 mm3) using four different radiation plans (see methodology), two collimators (3 mm 
and 5 mm), and a prescribed dose of 2 Gy
Structure
Collimator 3 mm 5 mm
Plan 1 2 3 4 1 2 3 4
ITV
Dmean (Gy) 2.00 1.99 2.00 1.98 2.02 1.99 2.01 2.00
Dmin (Gy) 1.57 1.72 1.78 1.77 1.94 1.91 1.92 1.91
Dmax (Gy) 2.16 2.18 2.16 2.16 2.16 2.14 2.14 2.17
V95 (%) 98.03 99.69 99.11 95.67 100.00 100.00 100.00 100.00
D95 (Gy) 1.93 1.94 1.94 1.90 1.98 1.95 1.97 1.95
D5 (Gy) 2.07 2.07 2.07 2.06 2.10 2.07 2.09 2.08
D1 (Gy) 2.12 2.11 2.11 2.12 2.13 2.10 2.12 2.13
PTV
Dmean (Gy) 1.96 1.99 1.98 1.97 2.06 2.03 2.05 2.04
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 2.20 2.18 2.17 2.20 2.20 2.17 2.18 2.20
V95 (%) 86.61 92.80 86.68 82.29 99.88 99.94 99.95 99.83
D95 (Gy) 1.46 1.80 1.68 1.67 1.98 1.96 1.97 1.94
D5 (Gy) 2.11 2.11 2.10 2.12 2.14 2.10 2.12 2.14
D1 (Gy) 2.14 2.13 2.13 2.15 2.16 2.12 2.14 2.16
Right lung  
Dmean (Gy) 0.73 0.35 0.54 0.51 1.22 0.61 0.91 0.87
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 2.21 2.20 2.17 2.22 2.22 2.17 2.18 2.24
V95 (%) 24.55 11.20 4.54 4.20 47.73 21.74 15.15 14.50
D95 (Gy) 0.01 0.00 0.01 0.01 0.02 0.01 0.02 0.02
D5 (Gy) 2.10 2.04 1.84 1.82 2.13 2.08 2.08 2.09
D1 (Gy) 2.13 2.10 2.07 2.08 2.16 2.11 2.11 2.15
Left lung  
Dmean (Gy) 0.01 0.57 0.29 0.24 0.01 0.98 0.48 0.39
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 0.02 2.24 1.14 0.95 0.03 2.22 1.14 0.97
V95 (%) 0.00 19.26 0.00 0.00 0.00 36.68 0.00 0.00
D95 (Gy) 0.00 0.01 0.01 0.01 0.00 0.02 0.01 0.01
D5 (Gy) 0.01 2.11 1.06 0.77 0.02 2.13 1.08 0.86
D1 (Gy) 0.01 2.16 1.09 0.86 0.02 2.15 1.10 0.91
Heart Dmean (Gy) 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.07
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 0.11 0.13 0.09 0.69 1.82 1.79 0.93 0.94
V95 (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
D95 (Gy) 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01
D5 (Gy) 0.02 0.02 0.02 0.11 0.04 0.04 0.04 0.42
D1 (Gy) 0.02 0.02 0.02 0.41 0.31 0.11 0.27 0.72
(Continued)
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occurrence of mediastinal nodal metastasis, and death after 19 
days.27 One of the tumors (D8) in this study presented a centrally 
located bone-like dense structure (possibly a calcification), which 
not only delayed H1299-luciferase tumor growth considerably, but 
also affected the DVH metrics in radiation planning. In the clinic, 
this event occurs in 10.6% of lung carcinomas,28 therefore optimal 
radiation treatment strategies are needed.
We have shown that tumor growth in the mouse lung can be 
monitored over time using two non-invasive imaging modalities 
(CBCT and BLI), and can provide quantitative or semi-quanti-
tative temporal information on tumor volume, respectively. Our 
data on orthotopic lung tumors are in line with our previous data 
and that of others, on orthotopic brain tumors, where correla-
tion between CBCT and BLI have been reported in context of 
radiotherapy combination treatments.15,17,18,29,30 For orthotopic 
lung tumor models, Madero et al has shown that BLI signal from 
A549 tumors had a strong correlation with the histologically 
determined tumor burden.31 It has also been observed in orthot-
opic mouse LLC tumors that 80kV micro-CT tumor volume is 
correlated with BLI intensity.21 These data are in line with our 
study and we extended these findings using human cell lines by 
showing that CT and BLI correlate, in both the open modus as 
well as using selective wavelength filters (655 and 591.5 nm). 
This addition can set a base for further research and algorithm 
development to obtain spatial information from BLI data. Other 
studies have also reported correlation between imaging tech-
niques in orthotopic lung tumors:19 -FDG-PET imaging and BLI 
with A549 tumors32 and MRI using gadolinium-nanoparticles, 
and BLI with H358-Luciferase tumors.33
Using a preclinical orthotopic NSCLC model, we demon-
strated the feasibility of image-guided radiotherapy using a 
small animal irradiator. Deviations due to respiration can 
lead to an overestimation of the mean tumor dose of up to 
11% as assessed with 4D-MOBY phantoms,34 but these devi-
ations were avoided by acquiring images in a 2 min time 
frame, similar to a “slow” CBCT scan in the clinic. Gating for 
respiratory motion was not applied in this study and remains 
understudied preclinically. In the clinic, a 5 mm clinical target 
volume margin35 is applied. Given that the tumors we worked 
with in this study have a smooth surface, localized position, 
and errors due to breathing motion are accounted for by doing 
a slow (in relation to the breathing frequency of the mouse) 
CBCT scan, we suggested a PTV margin of 0.5 mm to take 
into account the error associated with a difference in voxel 
size. Delineations of the tumor and OAR were done using 
pre-defined window settings, slightly broader than previ-
ously described.36 Because the measured volume of tumors in 
the lung is highly dependent on the window width and level 
used during analysis as has been previously reported,35 these 
parameters were kept constant in our study. Furthermore, we 
acquired BLI emission at different wavelengths. It has been 
recently described that the tissue penetrance of the 655 nm 
wavelength is ~2 mm and that of the 591.5 nm is of ~1 mm 
using low-level laser therapy in human skin.37 Our results 
suggest that given the difference in signal intensity between 
wavelengths, algorithms could be developed to determine the 
spatial location of tumors. Such advances would be necessary 
to further the use of BLI as an alternative modality to CBCT 
for radiation-treatment planning.
Four different treatment plan setups with two different collimators 
for two different tumor sizes were investigated to define the optimal 
treatment plan (maximum homogeneous dose to the tumor and 
minimum dose to OAR). We observed that the 5 mm collimator 
gives the best tumor coverage for both volumes but comes with 
an enhanced dose to healthy lung for smaller tumors. Our results 
indicate that parallel-opposed static beams give a better tumor 
coverage for the 3 mm collimator while there was no difference 
for a 5 mm collimator. This is in line with our previous results for 
orthotopic brain tumors using two static parallel-opposed beams.17 
Parallel-opposed single–angle beams through one lung are advised 
since there is only a slight reduction in V95 for PTV compared to 
plans that cross-both lungs, but there is less dose to the healthy 
lung. However, because there may be changes in normal tissues 
throughout the course of radiotherapy, it has been advised to 
complement the DVH metric analysis with biomarkers or imaging 
features in predictive model calculations.38 For a smaller tumor, 
we recommend to use a 3 mm collimator and a parallel-opposed 
Structure
Collimator 3 mm 5 mm
Plan 1 2 3 4 1 2 3 4
Spinal cord
Dmean (Gy) 0.01 0.01 0.01 0.01 0.04 0.11 0.06 0.06
Dmin (Gy) 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00
Dmax (Gy) 0.07 0.51 0.24 0.31 0.88 1.94 1.01 0.85
V95 (%) 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00
D95 (Gy) 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01
D5 (Gy) 0.02 0.03 0.02 0.02 0.08 0.69 0.30 0.33
D1 (Gy) 0.03 0.06 0.04 0.07 0.38 1.61 0.83 0.67
Dmax, maximum PTV dose (Gy); Dmean, mean PTV dose (Gy); Dmin, minimum PTV dose (Gy); ITV, internal target volume; PTV, planned target 
volume; V95, Percentage (%) of PTV receiving 95% of the prescribed dose.
Dmean: Mean PTV dose (Gy),Dmin: Minimum PTV dose (Gy), Dmax: Maximum PTV dose (Gy), V95: Percentage (%) of PTV receiving 95% of 
the prescribed dose, and D95, D5, D1 are the doses to the hottest 95%, 5%, or1% delineated structure.
Table 1. (Continued)
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Table 2. Dose–volume histogram metrics for different structures (ITV, PTV, right/left lung, heart, spinal cord) for a representative 
mouse case bearing a H1299-wt tumor (10.4 mm3) using four different radiation plans (see methodology), two collimators (3 mm 
and 5 mm), and a prescribed dose of 2 Gy
Structure
Collimator 3 mm 5 mm
Plan 1 2 3 4 1 2 3 4
ITV
Dmean (Gy) 1.94 1.95 1.95 1.94 1.98 1.99 1.99 2.00
Dmin (Gy) 0.58 0.73 0.90 1.20 1.88 1.89 1.90 1.90
Dmax (Gy) 2.14 2.15 2.15 2.16 2.15 2.15 2.14 2.18
V95 (%) 85.34 87.28 87.6 79.13 99.87 99.98 99.99 99.91
D95 (Gy) 1.68 1.78 1.76 1.77 1.94 1.94 1.95 1.94
D5 (Gy) 2.04 2.03 2.04 2.03 2.06 2.06 2.06 2.08
D1 (Gy) 2.08 2.08 2.09 2.09 2.09 2.09 2.09 2.13
PTV
Dmean (Gy) 1.79 1.86 1.84 1.83 2.01 2.02 2.02 2.03
Dmin (Gy) 0.04 0.07 0.17 0.48 1.69 1.88 1.84 1.77
Dmax (Gy) 2.19 2.16 2.15 2.16 2.16 2.17 2.16 2.20
V95 (%) 69.83 76.85 65.81 58.17 98.66 99.98 99.88 99.45
D95 (Gy) 0.71 1.02 1.23 1.27 1.93 1.95 1.95 1.94
D5 (Gy) 2.08 2.07 2.07 2.07 2.09 2.10 2.09 2.14
D1 (Gy) 2.12 2.10 2.10 2.11 2.11 2.12 2.11 2.16
Right lung  
Dmean (Gy) 0.54 0.32 0.43 0.37 0.98 0.61 0.80 0.69
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 2.21 2.20 2.15 2.16 2.18 2.17 2.18 2.22
V95 (%) 17.68 9.89 2.25 1.80 34.98 21.00 10.96 10.14
D95 (Gy) 0.01 0.00 0.01 0.01 0.02 0.01 0.02 0.01
D5 (Gy) 2.07 2.02 1.44 1.36 2.08 2.08 2.04 2.05
D1 (Gy) 2.11 2.08 2.02 1.99 2.11 2.10 2.09 2.13
Left lung  
Dmean (Gy) 0.01 0.47 0.26 0.20 0.01 0.97 0.49 0.37
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 0.02 2.21 1.14 0.97 0.04 2.20 1.12 1.00
V95 (%) 0.00 15.03 0.00 0.00 0.00 35.06 0.00 0.00
D95 (Gy) 0.00 0.01 0.00 0.00 0.01 0.02 0.01 0.01
D5 (Gy) 0.01 2.07 1.05 0.79 0.02 2.12 1.07 0.90
D1 (Gy) 0.01 2.13 1.08 0.89 0.03 2.14 1.08 0.94
Heart Dmean (Gy) 0.01 0.01 0.01 0.07 0.04 0.02 0.03 0.13
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 1.49 0.03 0.75 1.27 2.07 1.08 1.05 1.78
V95 (%) 0.00 0.00 0.00 0.00 0.11 0.00 0.00 0.00
D95 (Gy) 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01
D5 (Gy) 0.02 0.01 0.02 0.54 0.05 0.04 0.05 0.82
D1 (Gy) 0.03 0.02 0.02 0.84 1.17 0.06 0.59 0.90
(Continued)
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single-angle treatment plan crossing a single lung. For larger orthot-
opic lung tumors, a 5 mm collimator is preferred using a beam plan 
that spreads the dose to the healthy tissue (parallel-opposed multi 
angle or arc treatment).
In conclusion, BLI and CBCT of orthotopic lung tumors provide 
complementary information regarding tumor growth. CBCT 
is preferably used for radiotherapy treatment planning, while 
BLI for monitoring tumor progression and treatment response. 
The optimal treatment plan, taking into account highest tumor 
coverage and lowest dose deposition in healthy tissue, may 
depend on tumor volume.
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Structure
Collimator 3 mm 5 mm
Plan 1 2 3 4 1 2 3 4
Spinal cord
Dmean (Gy) 0.01 0.01 0.01 0.01 0.06 0.03 0.05 0.04
Dmin (Gy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dmax (Gy) 0.19 0.19 0.11 0.23 4.46 2.88 2.33 2.06
V95 (%) 0.00 0.00 0.00 0.00 0.06 0.01 0.01 0.00
D95 (Gy) 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00
D5 (Gy) 0.02 0.02 0.02 0.02 0.24 0.09 0.21 0.21
D1 (Gy) 0.03 0.03 0.02 0.04 0.92 0.40 0.50 0.47
Dmax, maximum PTV dose (Gy); Dmin, minimum PTV dose (Gy); V95, percentage (%) of PTVreceiving 95% of the prescribed dose, and D95, 
D5, D1 are the doses to the hottest 95%, 5%, or 1% delineated structure.
Dmean: Mean PTV dose (Gy),Dmin: Minimum PTV dose (Gy), Dmax: Maximum PTV dose (Gy), V95: Percentage (%) of PTV receiving 95% of 
the prescribed dose, and D95, D5, D1 are the doses to the hottest 95%, 5%, or 1% delineated structure.
Table 2. (Continued)
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